Use of oxytocin and misoprostol for induction or ... - POPPHI

More documents

Recommendations

Info

Table 2.1a Inclusion and exclusion criteria used in the searches Category Inclusion Exclusion Rationale General Study design Time Rate Trend Quantitative Retrospective or prospective Randomized controlled trials Case/control Descriptive Meta-analysis Qualitative Last 20 years for LRS < 1988 Key objective of the review is the compilation of rates and trends Last 10 years for HRS < 1998 Dates restricted due to high volume of data from LRS which is not the primary focus of the review Setting Health facility Indications / clinical criteria Method Last 3 years for misoprostol High resource setting Low resource setting Health center District hospital Teaching hospital Pre-eclampsia Post dates Infection IUFD PROM > 24 hrs Suspected fetal compromise Elective Cervical ripening with misoprostol Induction with oxytocin or misoprostol Augmentation with oxytocin < 2004 Preterm Previous C/S Multiple gestation Suspected macrosomia Herbal Homeopathics Acupuncture Intercourse Nipple stimulation Evening primrose oil Stripping of membranes ARM Mechanical dilators (ie. catheter, laminaria) Castor oil Significant change in acceptable dosage of misoprostol for safe use for induction of labor established in 2004. HRS data used for comparative purposes only. Key objective of the review is the compilation of data on LRS practices Objective of review is to compile data on practices at all levels of the health system The issue of induction with a history of prior Cesarean section or with multiple gestation is controversial and contraindicated in LRS Suspected fetal macrosomia is not a valid indication for induction The three terms included in the search are often used interchangeably in the literature, making it difficult to exclude any of them Non-pharmacological methods are outside of the scope of this review given its focus on uterotonic drugs Only three systematic reviews will be considered in for ARM, stripping of the membranes and mechanical dilators for purposes of 17
Category Inclusion Exclusion Rationale recommendations and discussion Drugs Outcomes Oxytocin Misoprostol Maternal: Cesarean section following induction, uterine hyperstimulation, uterine rupture, mortality; Perinatal: hypoxia, significant morbidity, mortality; All other prostaglandins and uterotonics For the foreseeable future, the population of interest has access to these two drugs within the health system The database for this review was developed, pretested and revised as necessary. The database was compiled using Excel software. The searches resulted in identifying 962 articles from five databases; 278 references remained following review of the abstract; 140 references met the inclusion/exclusion criteria following full review of the article. Figure 2a provides an overview of the identification and inclusion process for the review of literature. 18
Page 1 and 2: Use of oxytocin and misoprostol for
Page 3 and 4: data from lower level and private f
Page 5 and 6: the literature provides us with ver
Page 7 and 8: Acronyms ACOG AMRN AMTSL CS EFM FDA
Page 9 and 10: List of Tables Table 1.1a Published
Page 11 and 12: 1. Introduction Low and middle inco
Page 13 and 14: Comment Setting Country Source and
Page 15 and 16: 4) To summarize current rates, tren
Page 17: eview given its focus on the use of
Page 21 and 22: Table 3.1a provides definitions for
Page 23 and 24: Prerequisite clinical conditions fo
Page 25 and 26: practitioner’s discretion as outl
Page 27 and 28: Table 3.3c WHO recommendations for
Page 29 and 30: Table 3.4a National induction rates
Page 31 and 32: variable induction rates in Washing
Page 33 and 34: Table 3.4c: The percent distributio
Page 35 and 36: studies that assessed this outcome.
Page 37 and 38: 3.5 Rates, Trends, Indications and
Page 39 and 40: Tables 3.5b presents rates of induc
Page 41 and 42: Table 3.5d Hospital-specific rates
Page 43 and 44: adverse outcomes of induction becau
Page 45 and 46: this is not associated with increas
Page 47 and 48: use in LRS, particularly given the
Page 49 and 50: Sweeping of the membranes was compa
Page 51 and 52: concern regarding its use for early
Page 53 and 54: Misoprostol is now available in som
Page 55 and 56: Figure 3.6 c World map showing glob
Page 57 and 58: documented rates of elective induct
Page 59 and 60: In general, definitions, descriptio
Page 61 and 62: An evidence-based safe and effectiv
Page 63 and 64: Appendix A: Glossary of common term
Page 65 and 66: References 1. World Health Organiza
Page 67 and 68: 28. Beebe LA, Rayburn WF, Beaty CM,
Page 69 and 70:
55. Maternity statistics, england:
Page 71 and 72:
81. Roberts CL, Algert CS, Douglas
Page 73:
105. Nigam A, Singh VK, Dubay P, Pa
show all

Use of oxytocin and misoprostol for induction or ... - POPPHI

Create successful ePaper yourself

Delete template?

Save as template?